GlassScriptPhysician profile
Tory Caudle
NPI 1851688485
$3,399.27
in general payments reported to CMS, 2019-2025
20 companies · $541 in 2025
The $541 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $468 · 2021: $285 · 2022: $435 · 2023: $590 · 2024: $777 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $924.94 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $554.43 | 2019-2024 | Jornay Pm |
| Corium, LLC | $530.67 | 2021-2025 | Azstarys, Azstarys |
| Glaxosmithkline, LLC. | $282.61 | 2019-2024 | Bexsero |
| Genzyme Corporation | $262.14 | 2024-2025 | |
| Neos Therapeutics, LP | $170.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.00 | 2020-2022 | |
| Dermira, INC. | $97.38 | 2019 | |
| Tris Pharma INC | $92.61 | 2020-2025 | Dyanavel Xr |
| Pfizer INC. | $79.02 | 2020-2025 | |
| Modernatx, INC. | $64.56 | 2023 | Moderna Covid-19 Vaccine |
| Merck Sharp & Dohme LLC | $42.66 | 2023-2024 | Gardasil 9, Gardasil |
| Neuraxis, INC. | $32.24 | 2024 | |
| Adlon Therapeutics L.P. | $31.66 | 2021 | |
| Vertical Pharmaceuticals, LLC | $29.44 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $20.97 | 2019 | |
| Sobi, INC | $17.59 | 2020 | |
| Sanofi Pasteur INC. | $17.31 | 2024 | |
| Collegium Pharmaceutical, INC. | $16.33 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $15.93 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tory Caudle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.